Navigation Links
Advaxis, Inc. phase I/II results of lovaxin C in cervical cancer study released
Date:10/10/2007

LYON, France & NORTH BRUNSWICK, N.J.--(October 10, 2007)--World Vaccine Congress: A first-in-man trial of a live Listeria vaccine was reported by Advaxis Inc. (OTCBB: ADXS - News). The Phase I/II trial was testing Lovaxin C in advanced cervical cancer patients. Lovaxin C is being developed by Advaxis as an immunotherapy that is intended to treat patients with cancers that result from human papilloma virus (HPV), including cervical cancer and head and neck cancer.

In the safety study, Advaxis reported treating fifteen patients in three dosage groups with thirty-minute 250 ml infusions of Lovaxin C at three-week intervals. Patients were observed for a total of 111 days. All patients had either advanced, recurrent, or progressive cervical cancer, and with the exception of two women, all patients were stage IVb (end stage). Every patient experienced a flu-like syndrome in the three-to-twelve hours after dosing comprised of fever, chills, nausea, and occasional vomiting, which is consistent with immune stimulation. In the lower two doses, symptoms were well tolerated and resolved with the use of over the counter analgesics and antihistamines. In the highest cohort the pattern of symptoms was the same, however more severe and dose limiting; which required that the study be stopped at that point as a dosage ceiling was defined. The endpoint of the study, safety, was met as the assessments confirmed that Lovaxin C was safe to administer intravenously, that the pattern of adverse responses observed, as previously stated above, were consistent with immune stimulation, and that, for this population of patients, a dosage ceiling was determined.

Although efficacy was not a primary endpoint anecdotal information was obtained. Patients' tumors were assessed by CT scans and any tumor changes were scored using RECIST criteria. Two patients had only a single tumor measurement, making the assessable efficacy population thirteen patients. It was observed that five patients progressed, seven patients were stable (defined by RECIST as changes in tumor sizes of under 30%), and one patient had a reduction of her tumor burden by 32%, qualifying as an objective partial response. Of the seven stable patients, three had reductions in their tumor mass subsequent to treatment. While most lesions increased in size, tumor reduction was seen in a number of lesions and two tumors disappeared completely. One patient, who was staged at IVb, had failed two prior courses of chemotherapy and one course of radiation. After treatment, she was deemed sufficiently healthy to resume chemotherapy and was removed from the trial early for this purpose. Following additional chemotherapy and surgery she is currently tumor free, with normal hematologic function, and all laboratories within normal limits.

"Our long held belief that live Listeria vaccines are safe, even in end stage cancer patients, has been confirmed by this study. We have just entered the age of safe bacterial therapies. This milestone has given us the direction for the continued development of Lovaxin C as well as future therapeutic agents," said Dr. John Rothman, VP of Clinical Development in assessing the trial data.


'/>"/>

Contact: Janet Vasquez
janet@investorrelationsgroup.com
212-825-3210
Advaxis, Inc.
Source:Eurekalert

Related medicine news :

1. FDA approves Phase 0 trial which tests experimental drugs on humans
2. SARS-Free Taiwan to Mark End Phase of Global Fight
3. S. Africa AIDS in death phase
4. Spray on contraceptive clears Phase I trial
5. Phase 3 trials of two multi-kinase inhibitors against cancer
6. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
7. Phase II trails of new HIV vaccine to be held in South Africa
8. Phase 1 Drug Trials on Humans to Be Made Public
9. Jalgaon: Third Phase Of Culling Operations Begin
10. Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P
11. Cadila to Commence Phase I Clinical Trials On ZYH2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... CT (PRWEB) , ... March 22, 2017 , ... ... historic plan to cure Rett Syndrome, a devastating neurological disorder that afflicts 350,000 ... MECP2, located on the X chromosome, and almost exclusively strikes females. Following ...
(Date:3/22/2017)... ... 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather Johnson and the ... in need of skilled pediatric dentistry in Rock Hill, SC, without a ... routine treatments, including cavities, sealants and fluoride applications, in a comfortable and fun environment. ...
(Date:3/22/2017)... York (PRWEB) , ... March 22, 2017 , ... ... Hospital have entered into a research collaboration to translate advances in basic neuroscience ... impairments at Blythedale and beyond. The collaboration seeks to improve movement, vision, and cognition ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... imaging core lab with extensive therapeutic experience and operational excellence in oncology clinical ... immuno-oncology clinical trial for the treatment of non-small cell lung cancer and small ...
(Date:3/22/2017)... ... March 22, 2017 , ... SNL Insurance ... to families and business owners in the greater Hampton Roads area, is embarking ... Society Relay For Life event. , Each year, hundreds of people living in ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017 FinancialBuzz.com News ... According to ... was worth an estimated $6.6 billion in 2016, and is projected ... or reaching more than $24 billion by 2025. The medical cannabis ... growing from $4.7 billion in 2016, to an estimated $13.3 billion ...
(Date:3/22/2017)... 2017 EMD Serono, the biopharmaceutical business of Merck ... and Canada , today announced two new ... session at the 65 th Annual Pacific Coast Reproductive ... on March 24 th .   The results ... collected from July 2009 to December 2015 containing data from ...
(Date:3/22/2017)... MarketNewsUpdates.com News Commentary  ... As ... oil continues to rise in popularity with consumers, Cannabis ... enhancing production through acquiring innovative assets and other plant ... include: Future Farm Technologies Inc (OTC: FFRMF) (CSE: FFT.CN), mCig, ...
Breaking Medicine Technology: